Infliximab was shown to be effective and safe in controlled trials of psoriatic arthritis (PsA).^1–,⁴ In an open-label study, we reported a notable clinical benefit accompanied by clearing and healing of psoriatic skin lesions.⁵ Thus, we conducted this study to evaluate the efficacy and safety of infliximab in patients with active PsA and recalcitrant psoriasis in whom treatment with disease-modifying antirheumatic drugs had failed. Thirty two patients who had a negative purified protein derivative skin test and normal chest radiographs were included. All had an active disease, defined as ⩾6 tender or swollen joints count, psoriasis area and severity index (PASI) score ⩾10,⁶ and erythrocyte sedimentation rate ⩾28 mm Hg/h or C reactive protein concentration …